GlassScriptPhysician profile
Peter J Sloane
NPI 1902867401
$1,248.68
in general payments reported to CMS, 2019-2025
25 companies · $27.20 in 2025
The $27.20 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,021 · 2020: $139 · 2021: $40.44 · 2022: $20.58 · 2025: $27.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $27.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $27.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $253.29 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.88 | 2019 | |
| Genentech USA, INC. | $154.79 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $120.78 | 2019-2022 | |
| Grifols USA, LLC | $78.35 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $44.58 | 2019 | |
| Jazz Pharmaceuticals INC. | $39.06 | 2019 | |
| Genzyme Corporation | $35.70 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $33.79 | 2019 | |
| Mylan Specialty L.P. | $31.34 | 2019 | |
| Fisher & Paykel Healthcare INC | $30.90 | 2020 | |
| Sunovion Pharmaceuticals INC. | $30.47 | 2019 | |
| Insmed, INC. | $27.83 | 2019 | |
| Vantive US Healthcare LLC | $27.20 | 2025 | Renal - Acute |
| Merck Sharp & Dohme LLC | $23.77 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $20.82 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.48 | 2019 | |
| Shire North American Group INC | $15.03 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $14.37 | 2019 | |
| Mallinckrodt Enterprises LLC | $13.81 | 2019 | |
| Allergan, INC. | $13.10 | 2019 | |
| Harmony Biosciences LLC | $13.09 | 2020 | |
| Biomerieux INC | $12.22 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.11 | 2019 | |
| Electromed, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Sloane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.